Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

The randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial (ClinicalTrials.gov identifier: NCT01757535) evaluated oral azacitidine (Oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC) who were not candidates for hematopoietic stem cell t...

Descripción completa

Detalles Bibliográficos
Autores principales: Döhner, Hartmut, Wei, Andrew H., Roboz, Gail J., Montesinos, Pau, Thol, Felicitas R., Ravandi, Farhad, Dombret, Hervé, Porkka, Kimmo, Sandhu, Irwindeep, Skikne, Barry, See, Wendy L., Ugidos, Manuel, Risueño, Alberto, Chan, Esther T., Thakurta, Anjan, Beach, C.L., Lopes de Menezes, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653004/
https://www.ncbi.nlm.nih.gov/pubmed/35960871
http://dx.doi.org/10.1182/blood.2022016293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653004/
https://www.ncbi.nlm.nih.gov/pubmed/35960871
http://dx.doi.org/10.1182/blood.2022016293

Ejemplares similares